A clinical trial testing the effectiveness of two prescription drugs for the skin condition psoriasis found significant differences in the doses needed to treat patients with the condition.

The trials, carried out at the UK’s University of Manchester, compared the relatively new biological therapies etanercept and ustekinumab.

The study found that there was at least a 75% improvement in the severity of psoriasis symptoms in 56.8% of patients who received twice-weekly 50mg subcutaneous injections of etanercept after 12 weeks.

For ustekinumab, a 75% improvement in symptoms was observed in 67.5% of patients taking the 45mg dose and 73.8% receiving the 90mg dose.